Estrogens and genomic instability in human breast cancer cells--involvement of Src/Raf/Erk signaling in micronucleus formation by estrogenic chemicals.
Reports of the ability of estrogenic agents such as 17beta-estradiol (E2), estriol (E3) and bisphenol A (BPA) to induce micronuclei (MN) in MCF-7 breast cancer cells have prompted us to investigate whether these effects are linked to activation of the estrogen receptor (ER) alpha. Coadministration of tamoxifen and the pure ER antagonist ICI 182 780 to cells treated with E2 and E3 did not lead to significant reductions in micronucleus frequencies. Since these antiestrogens interfere with the transcriptional activity of the ER and block promotion of ER-dependent gene expression, it appears that this process is not involved in micronucleus formation. However, ER activation also triggers rapid signaling via the Src/Raf/extracellular signal-regulated kinase (Erk) pathway. When MCF-7 cells were exposed to E2 and BPA in combination with the specific kinase inhibitors pyrazolopyrimidine and 2'-amino-3'-methoxyflavone, reductions in micronucleus frequencies occurred. These findings suggest that the Src/Raf/Erk pathway plays a role in micronucleus formation by estrogenic agents. Enhanced activation of the Src/Raf/Erk cascade disturbs the localization of Aurora B kinase to kinetochores, leading to a defective spindle checkpoint with chromosome malsegregation. Using antikinetochore CREST antibody staining, a high proportion of micronucleus containing kinetochores was observed, indicating that such processes are relevant to the induction of MN by estrogens. Our results suggest that estrogens induce MN by causing improper chromosome segregation, possibly by interfering with kinase signaling that controls the spindle checkpoint, or by inducing centrosome amplification. Our findings may have some relevance in explaining the effects of estrogens in the later stages of breast carcinogenesis.
The School of Pharmacy, University of London, Center for Toxicology 29-39 Brunswick Square, London WC1N 1AX, UK.
Alena
A
Kabil
Elisabete
E
Silva
Andreas
A
Kortenkamp
D001559:Benzhydryl Compounds; D001564:Benzo(a)pyrene / Q000633:toxicity; D001943:Breast Neoplasms / Q000235:genetics*; D045744:Cell Line, Tumor; D004958:Estradiol / Q000031:analogs & derivatives / Q000494:pharmacology; D004967:Estrogens / Q000633:toxicity*; D048049:Extracellular Signal-Regulated MAP Kinases / Q000037:antagonists & inhibitors / Q000502:physiology*; D005260:Female; D005419:Flavonoids / Q000494:pharmacology; D000077267:Fulvestrant; D042822:Genomic Instability; D006801:Humans; D018386:Kinetochores / Q000502:physiology; D048629:Micronuclei, Chromosome-Defective / Q000139:chemically induced*; D010636:Phenols / Q000633:toxicity; D011960:Receptors, Estrogen / Q000502:physiology; D015398:Signal Transduction / Q000187:drug effects*; D013629:Tamoxifen / Q000494:pharmacology; D048490:raf Kinases / Q000502:physiology*; D019061:src-Family Kinases / Q000037:antagonists & inhibitors / Q000502:physiology*; D000098826:Bisphenol A Compounds
D001559:Benzhydryl Compounds; D001564:Benzo(a)pyrene; D004958:Estradiol; D004967:Estrogens; D048049:Extracellular Signal-Regulated MAP Kinases; D005419:Flavonoids; D000077267:Fulvestrant; D010636:Phenols; D011960:Receptors, Estrogen; D013629:Tamoxifen; D048490:raf Kinases; D019061:src-Family Kinases; C006780:bisphenol A; D000098826:Bisphenol A Compounds; C093973:2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one